DuplexSeq™ Mutagenesis Assays: Error-Corrected Sequencing for Next-Generation Genomic Safety Assessment

Mutagenicity assessment is a critical component of nonclinical safety evaluation—directly linked to carcinogenic risk, regulatory decision-making, and program progression. As New Approach Methodologies (NAMs) gain traction and regulatory agencies increasingly recognize error-corrected sequencing technologies, development teams need practical guidance on integrating quantitative genomic safety endpoints into their testing strategies.

Watch this on-demand webinar featuring Matt Tate, PhD, Chief Business Development Officer at Scantox, presenting “DuplexSeq™ Mutagenesis Assays: Error-Corrected Sequencing for Next-Generation Genomic Safety Assessment,” recorded on March 12, 2026, and followed by a live Q&A session.

This session introduces DuplexSeq™ technology—an error-corrected next-generation sequencing platform that detects ultra-rare mutations and provides mutation frequency, spectra, and mechanistic signatures. The presentation explains how duplex sequencing works, explores its applications in genomic safety assessment, and outlines Scantox’s roadmap for technology transfer and market availability. Viewers will gain practical insight into how error-corrected sequencing can be integrated into genetic toxicology strategies and how to access DuplexSeq through both reagent kits and full CRO services.

Key Learning Objectives

• Understand how DuplexSeq™ technology works—tracking both DNA strands independently to eliminate sequencing errors and detect ultra-rare mutations at sensitivity levels not achievable with conventional NGS.
• Learn where error-corrected sequencing fits as a NAM in genomic safety assessment—from nitrosamine impurity programs requiring BMD modeling, to Ames-positive follow-up requiring tissue-specific context, to early safety visibility in repeat-dose studies.
• Discover how DuplexSeq™ provides mutation frequency plus mechanistic signatures (mutation spectra and trinucleotide context) to support mechanism-of-action interpretation and regulatory decision-making.
• Explore Scantox's technology transfer roadmap—including service launch timeline (H2 2026), delivery models (reagent kits vs. CRO service), and how DuplexSeq™ complements existing Big Blue® transgenic rodent capabilities.

Who Should Attend

• Nonclinical safety & genetic toxicology leads responsible for mutagenicity assessment strategies and regulatory packages.
• Nitrosamine and impurity teams working under regulatory pressure to generate in vivo mutation frequency data for benchmark dose modeling and Acceptable Intake limit derivation.
• Discovery and development project leaders seeking early genomic safety visibility and mechanistic insight to inform compound progression decisions.
• Regulatory affairs, CMC, and outsourcing managers evaluating how error-corrected sequencing and NAMs fit into integrated safety assessment programs.